{"analyses":[{"ciLowerLimit":"2.56","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"8.56","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Odds Ratio (OR)","paramValue":"4.68","statisticalMethod":"Cochran Mantel Haenszel chi-square test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.7","upperLimit":"37.5","value":"31.9"},{"groupId":"OG001","lowerLimit":"5.1","upperLimit":"15.0","value":"9.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"301"},{"groupId":"OG001","value":"152"}],"units":"Participants"}],"description":"Objective Response Rate (ORR) is defined as the percent of participants documented to have a confirmed complete response (CR) or partial response (PR). CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \\< 10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. All target lesions must be assessed. Disease progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with Adagrasib tablet or capsule orally at a starting dose of 600 mg twice a day (BID).","id":"OG000","title":"Adagrasib"},{"description":"Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with intravenous infusion of Docetaxel at 75 mg/m\\^2 over 1 hour or according to institutional practices.","id":"OG001","title":"Docetaxel"}],"paramType":"NUMBER","populationDescription":"Intent-To-Treat Population includes all participants who are randomized into this study.","reportingStatus":"POSTED","timeFrame":"From randomization till death or till disease progression or initiation of follow-up anti-cancer therapy or withdrawal of consent prior to minimum efficacy follow-up (up to 143 weeks)","title":"Objective Response Rate (ORR) as Per Blinded Independent Central Review","type":"SECONDARY","unitOfMeasure":"percentage of participants"}